What is the prevalence of Achondrogenesis?

Achondrogenesis is an ultra-rare, lethal form of skeletal dysplasia characterized by severe shortening of the limbs and trunk, with an estimated global incidence of approximately 1 in 40,000 to 1 in 50,000 live births. Due to the severe nature of the condition, most affected infants are stillborn or pass away shortly after birth, making long-term prevalence data for living individuals extremely limited.

How is the prevalence of Achondrogenesis categorized?

Achondrogenesis is classified as an ultra-rare condition. Because it is typically lethal in the neonatal period, the "prevalence" (the number of people living with the condition at a given time) is exceptionally low compared to its "incidence" (the number of new cases occurring annually). Accurate data is challenging to maintain, as cases are often reported as part of broader skeletal dysplasia registries rather than as a singular cohort.

Is there a difference in gender or ethnicity?

Clinical literature suggests that Achondrogenesis affects males and females with equal frequency. There is no evidence of ethnic or geographic predilection; the condition appears to occur globally across all populations. Current data indicates the following distribution factors:

• Age of onset: Achondrogenesis is diagnosed prenatally via ultrasound or immediately at birth, as it is a congenital, life-limiting condition.


• Classification: It is divided into three main types (IA, IB, and II), each with distinct genetic causes and clinical presentations.


• Data limitations: Underdiagnosis or misclassification as other forms of short-limb dwarfism can lead to an underestimation of true incidence rates.

Why is accurate data collection difficult?

The rarity of Achondrogenesis makes large-scale epidemiological studies difficult. Many cases are identified through prenatal screenings, but some may go misdiagnosed or unreported in regions with limited access to advanced genetic testing. At DiseaseMaps.org, 27 people have joined our community to share their experiences with Achondrogenesis, providing a vital, human-centered perspective that complements the clinical statistics found in medical journals.

Next steps

• Consult with a clinical geneticist to understand the recurrence risks associated with the specific subtype of Achondrogenesis.


• Connect with the DiseaseMaps.org community to find support and shared resources for families navigating this diagnosis.


• Request a referral to a specialized fetal medicine center if you are currently expecting or planning a pregnancy.

Medical disclaimer: This information is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Achondrogenesis.


• Orphanet: Rare Disease Database (ORPHA: 969).


• Online Mendelian Inheritance in Man (OMIM): Clinical synopsis for Achondrogenesis types.


• DiseaseMaps.org: Community insights and real-world patient data.